← All trials
NCT04032119
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2019
- Primary completion
- Aug 31, 2021
- Completion date
- Sep 30, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 800
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Chinese University of Hong KongLead sponsor
- Chinese University of Hong KongOverall official - principal investigator
- Chinese University of Hong KongReponsible party - principal investigator
- Changi General HospitalCollaborator
- University of ShizuokaCollaborator
- Osaka International Cancer InstituteCollaborator
- Kyoto 2nd Red Cross HospitalCollaborator
- Ishikawa Prefectural Central HospitalCollaborator
- Fukuoka UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.